The acute bacterial skin and skin structure infections market involves treating skin infections that are caused by various types of bacteria. These infections commonly affect the outer layer of the skin as well as underlying tissues and require treatment with antibiotics and topical medications. Some of the major types of skin infections managed include cellulitis, cutaneous abscesses, and infected wounds. The market has witnessed significant growth in recent years driven by the rising prevalence of skin infections around the world. According to the World Health Organization, over 13.5% of the global population is affected by various types of skin disorders each year. Additionally, increasing incidences of surgical site infections and diabetic foot ulcers have augmented the need for effective treatments against bacterial skin infections.
The global acute bacterial skin and skin structure infections market size is estimated to be valued at US$ 3,466.6 million in 2024 and is expected to exhibit a CAGR of 6.0% over the forecast period from 2023 to 2030.
Key Takeaways
Key players operating in the acute bacterial skin and skin structure infections market include Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc. These players are focusing on developing novel antibiotic formulations with improved efficacy. Additionally, the market is witnessing significant licensing and collaboration deals between pharmaceutical companies to expand their product portfolios.
The demand for antibiotic and topical treatments for acute bacterial skin infections is increasing tremendously owing to the rising prevalence of skin conditions such as cellulitis and abscesses globally. According to a study published in PLOS One, the global incidence rate of skin and soft tissue infections is estimated to be 450 per 100,000 persons annually.
Technological advancements have played a crucial role in improving patient outcomes for skin infection management. Some of the key developments include novel drug delivery systems such as injectable long-acting formulations and topical gels with enhanced permeability. Additionally, companies are investing in artificial intelligence and digital platforms to enable remote monitoring of infected wounds and surgical sites.
Market Trends
Increased Adoption of Combination Therapies: Combining two or more antibiotics is emerging as an effective treatment approach for antibiotic-resistant skin infections. Leading players are focusing on developing fixed-dose combination formulations.
Rise in E-commerce Sales: The COVID-19 pandemic has boosted the adoption of telemedicine and online pharmacies for acquiring antibiotic medications for skin infections. Key brands are partnering with e-pharmacies to improve accessibility.
Market Opportunities
Development of Rapid Diagnostic Tests: There is scope for innovative rapid diagnostic kits and tools for prompt detection of bacterial pathogens causing skin infections. This can help initiate early treatment.
Growing Demand in Emerging Nations: Emerging countries in Asia Pacific and Latin America with developing healthcare infrastructure present lucrative opportunities for antibiotics market players for conditions like acute bacterial skin infections.
Fastest Growing Region in Acute Bacterial Skin and Skin Structure Infections Market
The Asia Pacific region holds immense growth potential for the acute bacterial skin infections market and is poised to emerge as the fastest growing regional market during 2023-2030. This can be accredited to factors such as surging patient population, rising awareness about various skin conditions, growing healthcare expenditures, improving access to diagnosis and treatment options, increasing focus of global market players on emerging Asia Pacific countries due to favorable business environment, and expansion of private insurance coverage in the region. In particular, China and India represent highly lucrative markets owing to their huge population sizes and significant disease burdens. The growing collaborations between local and international pharmaceutical firms are also expected to boost product availability and uptake in Asia Pacific.